UNASSIGNED: Moringa stenopetala (Baker f.) Cudof. and Mentha spicata L. are widely used in the traditional system of medicine for the treatment of diabetes, hypertension, digestive problems and various disorders. The leaves formulation of M. stenopetala and M. spicata herbal tea showed better antidiabetic and antihypertensive effects in rodent models. However, its long-term safety profile has not been investigated yet. Thus, this study investigated the subchronic (90 days) oral toxicity of the leaves formulation of M. stenopetala and M. spicata herbal tea in Wistar albino rats.
UNASSIGNED: Four groups of rats (n = 10, with 5/sex/group) were randomly assigned into a control (vehicle) group and three test groups (559.36, 1118.72 and 2237.44 mg/kg, respectively). The three test groups received the herbal tea of M. stenopetala and M. spicata leaves blend daily for 90 days. The control group received distilled water. During the treatment period, clinical signs were observed daily, and food consumption and body weight changes of the rats were measured weekly. At the end of the experiment, macro-pathological, hematological and biochemical parameters were evaluated. Furthermore, histopathology of liver, kidney, heart, stomach and pancreas were examined.
UNASSIGNED: Subchronic oral administration of the herbal tea of M. stenopetala and M. spicata leaves blend did not result in death or significant toxicity signs in the treated group rats. Moreover, the herbal tea caused no significant changes on body weight, food intake, organ weight, hematological and biochemical parameters in either sex. However, the serum AST, CK and LDH levels were significantly elevated in rats treated with 2237.44 mg/kg of herbal tea in both sexes. There was no significant alteration in the histology of organs, only minor lesions in the liver, kidney and pancreas were observed.
UNASSIGNED: The study results indicate that the herbal tea of M. stenopetala and M. spicata leaves blend is relatively safe/low toxic to rats in subchronic exposure. However, further preclinical (chronic, teratogenic, reproductive and developmental toxicity) studies in animals are required in order to have sufficient safety and toxicity profiles for its use in humans.

Bacillary dysentery (shigellosis) continues to cause havoc worldwide, with a high infectivity rate. It causes bloody diarrhea, and around 99% of bacillary dysentery cases occur in developing countries. The objective of this study is to develop a polyherbal formulation with the scientific rationale in treating infectious bacillary dysentery disease. The anti-bacterial activity, the minimum inhibitory concentration of the formulation against bacillary dysentery, causing microbes like Shigella flexneri (MTCC 1457), Escherichia coli (MTCC 1687), and Salmonella enterica (MTCC 98), was analysed by well-diffusion method and broth dilution method, respectively. The biofilm inhibition activity was determined on 96 well polystyrene plates and anti-quorum sensing activity by Chromobacterium violaceum CV026. The cytotoxicity was examined by acute oral toxicity. Excreta and organ bacterial load were analyzed by serial dilution method. The formulation efficacy was determined by analyzing the blood sample of rats. The antimicrobial efficacy of the developed formulation was calculated by measuring the zone of inhibition which was found to be 24 mm, 25 mm, and 25 mm, and the MIC values of 1.5 mg/ml, 1.5 mg/ml, and 2.0 mg/ml against S. flexneri, S. enterica, E. coli, respectively. The results show that the polyherbal formulation significantly reduced biofilm formation and has anti-quorum sensing activity. The formulation also effectively decreases the bacterial load and increases the K+, Na+, and Ca++ ions in animals treated with the formulation. The developed formulation was found to be non-toxic and effective against bacillary dysentery; thus, it can be used for treating bacillary dysentery and related complications.

BACKGROUND: In Ayurveda, several herbs and formulations are available for the treatment of Urolithiasis. However, they are not systematically evaluated for their safety, efficacy, indication and limitations. Herbmed Plus is one such herbal formulation that has been known for the management of urinary tract disorders. An attempt has been made to evaluate its efficacy on Urolithiasis.
OBJECTIVE: To evaluate the efficacy and safety of Herbmed Plus in urolithic rats.
METHODS: A total of 60 Wistar albino rats were used for this study. The male and female rats were divided into five groups: disease control, test (dose 90 mg/kg), standard I (Cystone), standard II (Alkaston insta) and normal control (six in each group). Urolithiasis was induced using ethylene glycol 0.75% in drinking water for 28 days. The rats with urinary oxalate crystals were dosed with oral test or standard treatments for 28 days.
RESULTS: All the animals appeared normal and showed no clinical signs of toxicity. None of the groups reported mortality or adverse effect on body weight and food consumption. The treatment with test drug showed improvement in the SGPT level and urine output (5.4 vs 3.47 mL/24 h). A drastic reduction in number of crystals were observed in male 0.5 vs 22 and female rats 0 vs 22.7 in test and disease group. The kidney lactate dehydrogenase, alkaline phosphatase, urinary phosphorus and calcium oxalate level decreased in the test and standard drug groups as compared to disease groups. Microscopy of the urine samples showed reduction in the number of crystals after treatment compared to the urolithic group. Increase in citrate levels in urine in all the treatment groups indicated anti-urolithiatic activity. The test group showed a 69.70% recovery in males and 47.57% recovery in female rats compared to the disease control group.
CONCLUSIONS: Herbmed Plus showed a significant reduction in oxalate synthesizing enzymes suggesting anti-urolithiatic activity and anti-inflammatory and regenerative property in cellular injury caused by crystal deposits.

BACKGROUND: Urolithiasis is a growing problem worldwide. Many a times, asymptomatic stones are kept under observation. Many herbal preparations are available for the same, but they lack proper scientific documentation.
OBJECTIVE: To study the anti-urolithiatic effect of an herbal preparation, Subap Plus (IP) capsules in patients with asymptomatic renal calculi of size ranging from 4 to 9 mm.
METHODS: This was a prospective, randomized, double-blind, placebo-controlled clinical trial conducted in a tertiary care hospital in Pune, India. Patients with asymptomatic renal calculi of 4-9 mm size were randomized (1:1, block randomization) to one of the group Subap Plus (treatment group) or placebo (placebo group). The study outcome included change in visual analog scale (VAS), change in the surface area and density of calculi and their expulsion. Statistical analysis was performed using student\'s t-test and Chi-square test.
RESULTS: A total of 120 patients were screened and 84 were enrolled who met the eligibility criteria, of which 65 patients completed the trial (treatment, n = 34; placebo, n = 31). The VAS score significantly decreased in the treatment group (6.9-1.8) than placebo group (7.2-6.8) (p < 0.001). The surface area and density were decreased by 47.58% (p < 0.008) and 43.01% (p < 0.001), respectively, in the treatment group than the placebo group. The expulsion of calculi was significantly higher in the treatment group than placebo group (20.59 vs. 3.23%, p < 0.03).
CONCLUSIONS: Patients treated with herbal formulation showed better expulsion rate and reduction in surface area and density than the placebo group.

To examine the effect of \"DeepaniyaVati\", a herbal formulation in the management of hyperlipidemia, a randomized group pre-test post-test study trial was carried out on fifty male (30 to 70 yrs) hyperlipidemic volunteers who were asked to follow their normal routine diet and activity pattern throughout the investigation period. The formulation, prepared by mixing nine plant products in equal proportion, when given in a daily dose of 2g, twice a day for a period of one month, brought about an observable improvement in all the lipid parameters by significantly reducing total cholesterol (10%), low density lipoprotein cholesterol (12.76%), very low density lipoprotein cholesterol (27.4%), triglycerides (34.7%) and bringing these values much nearer to the normal levels. In control group, no such effect was noticed. A concomitant significant increase in the HDL-C levels suggests the possible utility of \"Deepaniya Vati\" in the management of hyperlipidemia and the need for further detailed study.